



Timothy H. Ehrlich

PARTNER

Boston

P +1 617 648 9399

Tim is a partner in our Boston office and is chair of the firm's Life Sciences practice group.

Tim represents start-up, emerging growth and public life science companies in the biotechnology, pharmaceutical, medical device, diagnostics and healthcare IT industries. His practice spans the entire corporate lifecycle, from formation through liquidity, and he regularly serves as principal outside or general counsel to his clients. Tim is broadly experienced in business formation and entity selection, deal structuring, equity and debt financing transactions, general corporate and governance matters, M&A events and public offerings. Tim also has particular expertise in structuring and negotiating strategic alliances, including "bet-the-company" intellectual property collaborations and joint ventures, and providing strategic counseling and advice regarding intellectual property protection and commercialization. In addition to his company client counsel, Tim represents venture capital funds and institutional investors in their life science financing activities.

Tim has spoken in numerous forums and authored articles on corporate structuring and capital raising, technology licensing and intellectual property matters and related

business strategies that affect strategic alliances. He is also a co-author of the treatise “Corporate Partnering, Structuring and Negotiating Domestic and International Strategic Alliance” (Aspen Publishers).

Tim has been an advisor to the Harvard Law Entrepreneurship Program at Harvard Law School and the Harvard University iLab since their inception. In addition, Tim is a founder and director of Gursha, Inc., a charitable organization dedicated to supporting underserved children in Ethiopia. He is also a board member of Community Rowing Inc., a non-profit organization dedicated to creating opportunities for people of all backgrounds, abilities, and experience to grow through the sport of rowing.

Tim received his J.D., *cum laude*, from Harvard Law School, where he was an editor of the Harvard Journal of Law and Technology. He received an A.B., *summa cum laude*, from Princeton University, where he was elected to Phi Beta Kappa, selected as a national finalist for the Rhodes Scholarship, and was a four-year member of the 1993 national championship varsity squash team.

Before entering private practice, Tim served as a law clerk to the Honorable Thomas Penfield Jackson of the United States District Court in Washington, D.C., where he was primarily responsible for the case of US v. Microsoft.

Numerous industry groups and publications have recognized Tim as a national leader for his corporate and transactional work. LMG Life Sciences has named Tim a “Life Sciences Star” every year since 2012, has named him a nominee for its “VC Lawyer of the Year” award in 2020 and 2021 and awarded the firm the “VC Firm of the Year” honors in 2022.

Credentials

EDUCATION

- Harvard Law School, J.D.
cum laude
- Princeton University, A.B., Classics
summa cum laude
Phi Beta Kappa

BAR ADMISSIONS

- Massachusetts
- California (Inactive)

ACHIEVEMENTS

- *Massachusetts Lawyers Weekly*, Go-To Healthcare & Life Sciences Lawyer of the Year, Boston 2024
- Top Rated Attorney in Boston by *Super Lawyers*
- *LMG Life Sciences* “Life Sciences Star” since 2012

CLERKSHIPS

Hon. Thomas Penfield Jackson - United States District Court of Washington, D.C.

Focus Areas

Corporate Governance & Strategy
Fund Investments in Companies
Life Sciences Licensing & Strategic Partnering
Life Sciences
Mergers & Acquisitions
Public Companies/Public Offerings
Seed, Venture and Growth Financings

Gunderson Dettmer 2024 Venture Capital Report

Gunderson Dettmer released its 2024 Venture Capital Report, analyzing data collected from thousands of venture financing transactions in which we have represented clients.

In addition to the data analysis, Corporate Partners Tim Ehrlich, Steve Franklin, David Gammell, Mike Irvine, Melissa Marks, Ryan Purcell, Aaron Rubin and Heidi Walas offer their insights and commentary, drawing from their extensive experience as trusted market advisors.



Related News & Insights

INSIGHTS

Gunderson Dettmer Releases 2024 Venture Capital Report

CLIENT NEWS

Newleos Therapeutics Announces \$93.5M Series A for Next Generation Mental Health Therapies

CLIENT NEWS

Sherlock Biosciences Acquired by OraSure Technologies

CLIENT NEWS

Photys Therapeutics Announces Research Collaboration with Novo Nordisk

CLIENT NEWS

Muna Therapeutics Announces Research Alliance with GSK to Treat Alzheimer's Disease

EVENTS

One Nucleus Hosts Genesis 2024 Conference

CLIENT NEWS

Elevor Therapeutics Announces Exclusive Global Licensing Agreement with Relay Therapeutics for Lirafugratinib

CLIENT NEWS

Wellington Management Co-Leads \$215M Series B Financing of Metsera

CLIENT NEWS

Be Biopharma Announces \$82M Financing to Advance Gene Therapy

FIRM NEWS

Massachusetts Lawyers Weekly Recognizes Gunderson Dettmer Boston Partner Tim Ehrlich as a Massachusetts Go To Lawyer

CLIENT NEWS

QurAlis Enters into Strategic License and Collaboration Transaction with Eli Lilly for the Treatment of ALS and Frontotemporal Dementia

INSIGHTS

BioPharma Quotes Tim Ehrlich in "Biotech IPOs heated up to start 2024. Will the surge last?"

CLIENT NEWS

Kelonia Therapeutics Enters \$800M Research Collaboration and Licensing Agreement with Xyphos Biosciences